trending Market Intelligence /marketintelligence/en/news-insights/trending/0JIAdTi4QKqpYwrIW4xDcg2 content
Log in to other products

Login to Market Intelligence Platform

 /


Looking for more?

Contact Us
In This List

Hyundai Pharm secures rights to market hormone drug in South Korea

COVID-19 Pandemic Likely To Cause US Telemedicine Boom

Gauging Supply Chain Risk In Volatile Times

S&P Global Market Intelligence

Cannabis: Hashing Out a Budding Industry

Segment

IFRS 9 Impairment How It Impacts Your Corporation And How We Can Help


Hyundai Pharm secures rights to market hormone drug in South Korea

Hyundai Pharmaceutical Co. Ltd. secured rights to market Acerus Pharmaceuticals Corp.'s Natesto treatment in South Korea.

Financial terms of the agreement were not disclosed, though Acerus said it will receive an upfront payment followed by milestone-related payments upon regulatory approval of the product in South Korea.

The nasal gel is already available in U.S. and Canada for hormone-related deficiencies.